SARS-CoV-2 Antibody Profiling via Bacterial Peptide Display
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for SARS-CoV-2 lack sensitivity and specificity, and existing methods struggle to differentiate between shared epitopes from common coronaviruses and those specific to SARS-CoV-2, leading to diagnostic accuracy issues.
Innovation Solution
The development of a peptide display system using bacterial display technology coupled with next-generation sequencing to profile antibody repertoires and identify IgM and IgG antigenic epitopes as peptide motifs, specifically enriched for SARS-CoV-2, utilizing distinct peptide motifs that bind to SARS-CoV-2 antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional antigen-based diagnostic tests are used, then the testing process is simple, but the sensitivity and specificity are insufficient and cannot differentiate between shared epitopes from common coronaviruses and SARS-CoV-2 specific epitopes
Solution Approach 1:
The patent segments the coronavirus antigens into specific peptide motifs (e.g., RXX[CI]EXX[LI]F, RXXQE[DN]XXF, and other sequences listed in claims 1-20) that are displayed on bacterial surfaces. This segmentation allows the diagnostic test to target specific epitopes rather than whole antigens, enabling differentiation between shared and SARS-CoV-2 specific regions, thereby improving diagnostic accuracy while maintaining manageable complexity through modular peptide design.
Solution Approach 2:
The patent introduces bacteriophage-displayed peptides as an intermediary between the patient's antibodies and the detection system. These peptides serve as specific binding targets that mediate the interaction between SARS-CoV-2 antibodies and the diagnostic assay, allowing highly specific detection without requiring complex whole-antigen preparations. This intermediary approach resolves the contradiction by providing a simplified yet highly specific detection mechanism.
2Measurement precision
If whole antigens or protein lysates are used for antibody detection, then the assay is easy to perform, but the results are confounded by shared immunodominant epitopes from common coronaviruses
Solution Approach 1:
The patent extracts and isolates specific peptide motifs from whole coronavirus antigens. By taking out only the relevant epitopic regions (such as the RXX[CI]EXX[LI]F and RXXQE[DN]XXF motifs) and displaying them on bacterial surfaces, the assay eliminates confounding shared epitopes from common coronaviruses while retaining SARS-CoV-2 specific recognition sites. This extraction approach improves epitope specificity while simplifying the manufacturing process compared to purifying complex protein lysates.
Solution Approach 2:
The patent applies local quality by creating bacterial display systems where specific peptide motifs are presented at high density on the bacterial surface. This concentrates the diagnostic signal at the local level of individual peptide epitopes rather than distributing it across whole antigens. The local quality approach allows each peptide motif to be independently optimized for SARS-CoV-2 specificity while maintaining ease of manufacture through standardized bacterial expression systems.
3Reliability
If peptide display systems with multiple distinct peptides are used, then the diagnostic sensitivity and specificity are improved, but the system complexity increases
Solution Approach 1:
The patent merges multiple distinct peptide motifs (at least 2, preferably 3-20 different peptides as specified in claims 1-20) into a single bacterial display system. By combining these peptides on the surface of a single bacterium or in a small panel of bacteria, the system achieves high diagnostic reliability through multi-epitope recognition while keeping the overall device complexity manageable. The merging approach allows simultaneous detection of multiple antibody responses without requiring separate complex assays for each peptide.
Solution Approach 2:
The patent creates a universal bacterial display platform that can present multiple different peptide motifs through a single expression system. This multi-functional bacterium can display various SARS-CoV-2 epitopes simultaneously, allowing one system to perform multiple diagnostic functions. The universality of the bacterial expression system reduces device complexity compared to using separate purified proteins or complex antigen preparations for each peptide, while maintaining high diagnostic reliability through comprehensive epitope coverage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides highly specific and sensitive diagnostic panels for SARS-CoV-2 infection, capable of detecting asymptomatic exposure and tracking immune response kinetics, with improved accuracy compared to traditional antigen-based methods.
Implementation Method 1
The development of a peptide display system using bacterial display technology coupled with next-generation sequencing to profile antibody repertoires
Implementation Method 2
identify IgM and IgG antigenic epitopes, in the form of peptide motifs, that are diagnostic for SARS-CoV-2 infection
Data Source
AI summary
Disclosed herein are reagents for use in antibody profiling platforms, such as biopanning and Digital Serology, specifically for eptiope motifs directed to SARS-CoV-2. Also disclosed herein are kits, method of manufacturing, and methods of using the same.